Efficacy analysis of crizotinib for brain metastases in ALK-rearrangement-positive non-small cell lung cancer

黄伟; 王琳; 秦叔逵

doi:10.3969/j.issn.1007-3969.2015.06.010

您当前的位置：

首页 >

文章列表页 >

Efficacy analysis of crizotinib for brain metastases in ALK-rearrangement-positive non-small cell lung cancer

更新时间：2025-12-31

- Efficacy analysis of crizotinib for brain metastases in ALK-rearrangement-positive non-small cell lung cancer
- China Oncology Vol. 25, Issue 6, Pages: 468-472(2015)
- 作者机构：
  
  解放军八一医院全军肿瘤中心肿瘤内科,江苏,南京,210002
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.06.010
  CLC：
- Published Online：14 August 2015，
  
  Published：14 August 2015
- 稿件说明：
移动端阅览
黄伟,王琳,秦叔逵,等. 克唑替尼治疗ALK阳性非小细胞肺癌脑转移的疗效观察[J]. 中国癌症杂志, 2015, 25(6): 468-472.

黄伟, 王琳, 秦叔逵. Efficacy analysis of crizotinib for brain metastases in ALK-rearrangement-positive non-small cell lung cancer[J]. China Oncology, 2015, 25(6): 468-472.
黄伟,王琳,秦叔逵,等. 克唑替尼治疗ALK阳性非小细胞肺癌脑转移的疗效观察[J]. 中国癌症杂志, 2015, 25(6): 468-472. DOI： 10.3969/j.issn.1007-3969.2015.06.010.

黄伟, 王琳, 秦叔逵. Efficacy analysis of crizotinib for brain metastases in ALK-rearrangement-positive non-small cell lung cancer[J]. China Oncology, 2015, 25(6): 468-472. DOI： 10.3969/j.issn.1007-3969.2015.06.010.

摘要

背景与目的：克唑替尼对间变性淋巴瘤激酶(anaplastic lymphoma kinase，ALK)阳性非小细胞肺癌(non-small cell lung cancer，NSCLC)具有显著疗效，但在治疗中往往出现脑转移，本研究旨在探讨克唑替尼在ALK阳性NSCLC脑转移患者中的治疗疗效和治疗模式。方法：对2011年1月—2014年8月在解放军八一医院接受克唑替尼治疗的6例ALK阳性NSCLC脑转移患者的临床资料进行回顾性分析。结果：3例克唑替尼治疗前基线有脑转移患者，颅内疗效部分缓解(partial response，PR)1例、疾病稳定(stable disease，SD)2例；第1次服用克唑替尼治疗至第1次出现疾病进展(progressive disease，PD)的中位时间为5.7个月，且第1次疾病进展的部位均为脑。6例患者脑病灶进展接受放疗后继续服用克唑替尼治疗，中位无进展生存期(progression free survival，PFS)为4.0个月，其中1例患者继续接受克唑替尼治疗的PFS达23.3个月，颅内病灶疗效完全缓解(complete response，CR)。结论：克唑替尼治疗ALK阳性NSCLC脑转移患者有效，且对于单纯颅内病灶进展放疗后，继续接受克唑替尼治疗仍然有效，是临床上可以选择的治疗方式。

Abstract

Background and purpose: Although crizotinib could manifest marked antitumor activity in anaplastic lymphoma kinase (ALK)-rearrangement-positive non-small cell lung cancer (NSCLC) patients

but brain metastases is always occured in such patients. This study aimed to explore the efficacy and treatment mode of crizotinib for brain metastases in ALK-rearrangement-positive NSCLC. Methods: The clinical data of 6 patients with brain metastases in ALK-rearrangement-positive NSCLC treated in 81 Hospital of PLA from Jan. 2011 to Aug. 2014 were analyzed retrospectively. Results: Three patients had brain metastases before crizotinib administration

1 obtained partial response (PR) and 2 obtained stable disease (SD) in intracraninal tumors. The median progression free survival (PFS)for the first period of crizotinib administration were 5.7 months

and the sites of first disease progression were brains. All the 6 patients continued to receive crizotinib after radiotherapy with the median PFS of 4 months. One patient even experienced a median PFS of 23.3 months for the second period of crizotinib administration

and her brain tumors obtained complete response (CR). Conclusion: The data of this study suggest that crizotinib is effective for brain metastases in ALK-rearrangement-positive NSCLC

and continued administration of crizotinib after radiotherapy for isolated intracraninal tumor progression is a elective treatment option for such patients.

关键词

Keywords

references

Views

2006

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of ALK kinase domain drug resistance mutation and its future countermeasures

Clinical analysis of eleven adult patients with inflammatory myofibroblastic tumor

Patterns of the first failure in completely resected stage Ⅲ_A(N₂) non-small cell lung cancer

Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients

Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications

Related Author

Liyuan HE

Yudong WANG

张晓伟

王惠杰

张　琴

傅小龙

蔡旭伟

Qiling DENG

Related Institution

Department of Oncology, the Fourth Hospital Affiliated to Hebei Medical University

复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系

上海交通大学附属胸科医院放疗科

BSL-3 Laboratory(Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

AI问答

⁰